444 related articles for article (PubMed ID: 17306530)
1. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Bioorg Med Chem Lett; 2007 Apr; 17(8):2126-33. PubMed ID: 17306530
[TBL] [Abstract][Full Text] [Related]
2. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
[TBL] [Abstract][Full Text] [Related]
4. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.
Du J; Lei B; Qin J; Liu H; Yao X
J Mol Graph Model; 2009 Jan; 27(5):642-54. PubMed ID: 19081278
[TBL] [Abstract][Full Text] [Related]
5. Virtual screening of cathepsin k inhibitors using docking and pharmacophore models.
Ravikumar M; Pavan S; Bairy S; Pramod AB; Sumakanth M; Kishore M; Sumithra T
Chem Biol Drug Des; 2008 Jul; 72(1):79-90. PubMed ID: 18498326
[TBL] [Abstract][Full Text] [Related]
6. 3D QSAR studies on a series of potent and high selective inhibitors for three kinases of RTK family.
Cao H; Zhang H; Zheng X; Gao D
J Mol Graph Model; 2007 Jul; 26(1):236-45. PubMed ID: 17293140
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2.
Xie QQ; Xie HZ; Ren JX; Li LL; Yang SY
J Mol Graph Model; 2009 Feb; 27(6):751-8. PubMed ID: 19138543
[TBL] [Abstract][Full Text] [Related]
8. Modeling ligand-receptor interaction for some MHC class II HLA-DR4 peptide mimetic inhibitors using several molecular docking and 3D QSAR techniques.
Wei HY; Tsai KC; Lin TH
J Chem Inf Model; 2005; 45(5):1343-51. PubMed ID: 16180911
[TBL] [Abstract][Full Text] [Related]
9. A specific pharmacophore model of Aurora B kinase inhibitors and virtual screening studies based on it.
Wang HY; Li LL; Cao ZX; Luo SD; Wei YQ; Yang SY
Chem Biol Drug Des; 2009 Jan; 73(1):115-26. PubMed ID: 19152640
[TBL] [Abstract][Full Text] [Related]
10. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
Wei HY; Lu CS; Lin TH
J Mol Graph Model; 2008 Apr; 26(7):1131-44. PubMed ID: 18024210
[TBL] [Abstract][Full Text] [Related]
11. Potential choline kinase inhibitors: a molecular modeling study of bis-quinolinium compounds.
Srivani P; Sastry GN
J Mol Graph Model; 2009 Feb; 27(6):676-88. PubMed ID: 19147382
[TBL] [Abstract][Full Text] [Related]
12. Discovery of potential ZAP-70 kinase inhibitors: pharmacophore design, database screening and docking studies.
Sanam R; Vadivelan S; Tajne S; Narasu L; Rambabu G; Jagarlapudi SA
Eur J Med Chem; 2009 Dec; 44(12):4793-800. PubMed ID: 19674816
[TBL] [Abstract][Full Text] [Related]
13. Discovery of potent inhibitors of pseudomonal quorum sensing via pharmacophore modeling and in silico screening.
Taha MO; Al-Bakri AG; Zalloum WA
Bioorg Med Chem Lett; 2006 Nov; 16(22):5902-6. PubMed ID: 16945524
[TBL] [Abstract][Full Text] [Related]
14. Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors.
Zeng H; Zhang H
J Mol Graph Model; 2010 Aug; 29(1):54-71. PubMed ID: 20471293
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore and docking-based combined in-silico study of KDR inhibitors.
Pasha FA; Muddassar M; Neaz MM; Cho SJ
J Mol Graph Model; 2009 Aug; 28(1):54-61. PubMed ID: 19447057
[TBL] [Abstract][Full Text] [Related]
16. Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.
Usui T; Ban HS; Kawada J; Hirokawa T; Nakamura H
Bioorg Med Chem Lett; 2008 Jan; 18(1):285-8. PubMed ID: 17983745
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.
Lee K; Jeong KW; Lee Y; Song JY; Kim MS; Lee GS; Kim Y
Eur J Med Chem; 2010 Nov; 45(11):5420-7. PubMed ID: 20869793
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore identification, in silico screening, and virtual library design for inhibitors of the human factor Xa.
Krovat EM; Frühwirth KH; Langer T
J Chem Inf Model; 2005; 45(1):146-59. PubMed ID: 15667140
[TBL] [Abstract][Full Text] [Related]
19. 3D-QSAR and receptor modeling of tyrosine kinase inhibitors with flexible atom receptor model (FLARM).
Peng T; Pei J; Zhou J
J Chem Inf Comput Sci; 2003; 43(1):298-303. PubMed ID: 12546565
[TBL] [Abstract][Full Text] [Related]
20. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors.
Shih KC; Shiau CW; Chen TS; Ko CH; Lin CL; Lin CY; Hwang CS; Tang CY; Chen WR; Huang JW
Bioorg Med Chem Lett; 2011 Aug; 21(15):4490-7. PubMed ID: 21724393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
